Aegis Capital Downgrades Recro Pharma

Aegis Capital downgraded Recro Pharma Inc REPH Tuesday from Buy to Hold and did not set a price target.

Analyst Yi Chen noted that “Recro Pharma started a Phase 2 clinical trial of Dex-IN, its proprietary intranasal formulation of dexmedetomidine, in late October 2014 in the post-operative Day 1 setting for pain management following bunionectomy surgery.”

Regarding the current phase, Chen commented that “though theoretically the Day 1 setting should produce better efficacy than the Day 0 setting, investors ought to be cautious at this point, in our view.”

Chen cited a the previous Post Op Day 0 Phase 2 trial in September 2014 in which 95 received Dex-IN “with no serious adverse events, though four patients...discontinued due to symptomatic hypotension and one subject [discontinued] due to fever.”

With $23.9 million in cash at the end of September 30, 2014, Chen concluded “that the company shares currently trade at its cash value with a negative enterprise value. If the Day 1 Phase 2 trial reports positive data, the firm may need to raise additional capital by end-2015 for a Phase 3 trial.”

Recro Pharma Inc. recently traded at $2.77, down 4.57 percent.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: DowngradesAnalyst RatingsAegis Capitalyi chen
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!